Why PCOS Became PMOS — And Why This Matters for Women’s Health

For decades, millions of women have been told they have “polycystic ovary syndrome,” or PCOS. Yet many of those women never actually had ovarian cysts. The name confused patients, frustrated physicians, and often reduced a complex whole-body condition to a problem of the ovaries alone.

Now, after years of international debate, research, and advocacy, PCOS has officially been renamed PMOS — Polyendocrine Metabolic Ovarian Syndrome.^1

At first glance, this may seem like a small change in terminology. It is not. It represents a major shift in how medicine understands this condition and, hopefully, how women affected by it will be diagnosed, treated, and taken seriously.

The term “polycystic ovary syndrome” has long been criticized as medically inaccurate.

The “cysts” seen on ultrasound in PCOS are not actually ovarian cysts in the traditional sense. They are immature follicles — eggs that began development but did not fully mature or ovulate. Many women with the condition do not even have this ovarian appearance at all, while many women without the syndrome do.^2

The old name also focused attention almost entirely on reproduction and fertility, while minimizing the broader endocrine and metabolic implications of the disorder.

Yet anyone who regularly treats women with PCOS knows this condition extends far beyond irregular periods and infertility.

Women may struggle with:

• insulin resistance
• weight gain or difficulty losing weight
• inflammation
• elevated androgens
• acne and excess hair growth
• fatty liver disease
• increased cardiovascular risk
• sleep disturbances
• anxiety and depression
• long-term risks of diabetes and metabolic syndrome

This is not simply an ovarian disorder. It is a systemic condition involving multiple hormonal pathways and metabolic processes.

The old name did not reflect that reality.

This was not a spontaneous decision by a single organization.

The renaming process took approximately 14 years and involved an unprecedented international collaboration among researchers, endocrinologists, gynecologists, patient advocacy groups, and women living with the condition themselves.^3

The initiative was led largely by Professor Helena Teede and an international steering committee that included the International Androgen Excess and PCOS Society, patient advocacy organizations such as Verity UK, and dozens of professional and patient organizations worldwide.^3

More than 14,000 patients and healthcare professionals participated in surveys and consensus discussions globally.^2

The final consensus paper was published in The Lancet in 2026 and formally presented at the European Congress of Endocrinology.^1

The transition to the new terminology is expected to occur gradually over the next several years.^4

The new term — Polyendocrine Metabolic Ovarian Syndrome — was chosen deliberately.

Each part reflects a different aspect of the disorder:

• Polyendocrine: multiple hormonal systems are involved
• Metabolic: insulin resistance and metabolic dysfunction are central features
• Ovarian: reproductive and ovulatory dysfunction still matter
• Syndrome: it presents differently from woman to woman

Importantly, the new name shifts the conversation away from “cysts” and toward the underlying biology of the condition.

That matters.

Words shape perception. Perception shapes diagnosis. Diagnosis shapes treatment.

One of the greatest concerns surrounding PCOS has been delayed diagnosis. Many women are told their symptoms are “normal,” that they simply need to lose weight, or that their irregular cycles are not important.

Some women go years before receiving answers.

By reframing the condition as a metabolic and endocrine disorder — not simply a reproductive issue — clinicians may begin screening earlier and more comprehensively.^5

This could be particularly important in adolescents, where acne, irregular cycles, insulin resistance, and weight gain are often dismissed or normalized.

The new terminology emphasizes that this condition has lifelong implications.

Women with PMOS are at increased risk of:

• type 2 diabetes
• cardiovascular disease
• hypertension
• sleep apnea
• fatty liver disease
• infertility
• pregnancy complications
• endometrial hyperplasia and cancer

The name change may encourage clinicians to think more broadly about prevention and long-term metabolic health rather than focusing solely on fertility.^6

Many women with PCOS have been frightened after hearing they have “cysts” on their ovaries, believing they have tumors or permanent ovarian damage.

Others without visible ovarian findings questioned whether they truly had the condition.

The previous terminology created unnecessary confusion and anxiety. The new terminology aims to reduce that misunderstanding.^2

I believe this may ultimately be one of the most important outcomes.

The name PMOS better reflects what many clinicians in integrative and lifestyle medicine have recognized for years: this condition is deeply connected to metabolism, inflammation, nutrition, stress, sleep, environmental exposures, and overall health.

Women with PMOS deserve more than symptom suppression.

They deserve care that addresses:

• insulin resistance
• nutrition and blood sugar regulation
• sleep quality
• exercise and muscle health
• stress physiology
• inflammation
• endocrine disruptors and environmental toxins
• mental health support
• fertility optimization

This broader understanding may finally move treatment beyond “just go on the pill” and toward more individualized, root-cause approaches.

No.

Changing a name does not instantly fix gaps in women’s healthcare.

Diagnostic criteria have not substantially changed yet, and many clinicians will continue using the term PCOS during the transition period.^7

There will also be debate. Some experts argue the new name is still imperfect. Others question whether “ovarian” should remain in the title at all.^8

But despite these concerns, I believe the change represents meaningful progress.

For too long, women with this condition have lived with a name that minimized the complexity of what they were experiencing. PMOS is an attempt to align the terminology with the science — and with the lived experiences of millions of women worldwide.

As physicians, we sometimes underestimate the power of language.

Names influence research funding, public awareness, policy decisions, medical education, and how seriously patients are taken.

The shift from PCOS to PMOS acknowledges something important: this condition is not merely about ovaries. It is a whole-body endocrine and metabolic disorder that deserves earlier recognition, deeper research, and more comprehensive care.

Most importantly, it reminds us that women’s symptoms should never be dismissed simply because they are common.

Sometimes, changing the name is the first step toward changing the conversation.

1. Teede HJ, Gibson-Helm M, Azziz R, et al. “International Evidence-Based Recommendation on Polycystic Ovary Syndrome Name Change.” The Lancet. 2026.
2. Contemporary OB/GYN. “Global Consensus Renames PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS).” Published 2026.
3. Endocrine Society. “International Experts Announce Name Change from PCOS to PMOS.” Published 2026.
4. Live Science. “PCOS Gets a New Name After Years-Long Effort.” Published May 2026.
5. University of Colorado Anschutz Medical Campus News. “Why the PCOS Name Change Matters.” Published 2026.
6. The Guardian. “PCOS Renamed PMOS: What the New Name Means for Women’s Health.” Published May 2026.
7. Verywell Health. “Why PCOS Is Being Renamed PMOS.” Published 2026.
8. STAT News. “Why Experts Changed the Name of PCOS — and Why Some Still Aren’t Satisfied.” Published May 2026.

Dr Marina OBGYN